Science

Vascular dysfunction, caused by factors such as aging, genetic risk and diseases, including hypertension and diabetes, leads to the toxic accumulation of fibrin deposits outside of blood vessels, which sparks chronic innate immune cell activation.

Fibrin’s inflammatory epitope binds complement receptors CD11b/c on microglia, macrophages, and dendritic cells, triggering a toxic and chronic inflammatory response that is destructive to neurons and further erodes blood vessel walls.

Based on the work of world-renowned neurovascular and brain immunology expert and Therini Bio scientific founder Dr. Katerina Akassoglou, the Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at the University of California, San Francisco and Gladstone Institutes, we are developing potentially first-in-class, fibrin-targeting immunotherapies for the treatment of severe retinal and neurological diseases driven by vascular dysfunction.

Therini’s second candidate, THN622, is a bispecific antibody that simultaneously blocks fibrin’s inflammatory epitope and inhibits VEGF – uniting the proven efficacy of the current anti-VEGF standard of care with Therini’s neuroinflammation-targeting approach in a single molecule.